FTC OKs Actavis' $8B Warner Chilcott Buy With Conditions

Law360, New York (September 27, 2013, 4:53 PM ET) -- Actavis Inc. said Friday that it has agreed to sell rights to three oral contraceptives and an osteoporosis treatment to a New Jersey-based pharmaceutical company in order to settle Federal Trade Commission charges that the drugmaker's acquisition of Ireland’s Warner Chilcott PLC is anti-competitive.

Under the terms of a proposed settlement with the FTC, Actavis will sell its rights to the four drugs to Amneal Pharmaceuticals LLC. The agreement with U.S. regulators eliminates one of the last remaining regulatory hurdles blocking the creation of a new...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers